

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) ~~[[A]]~~ An isolated biopolymer marker selected from the group having a sequence identified as SEQ ID NO:1, SEQ ID NO:2 or at least one analyte thereof useful in indicating at least one particular disease state consisting of SEQ ID No:1 and SEQ ID NO:2.

Claims 2-38. (cancelled).

Claim 39. (new) A method for determining the presence of an isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 comprising:

- (a) obtaining a sample from a patient;
- (b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 to mass spectrum profiles of peptides

obtained and analyzed from said sample; and

(c) confirming the presence of said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in said sample displaying a peak profile at about 1624 daltons or at about 1552 daltons in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 is indicative of a link to Type II diabetes.

Claim 40. (new) The method of claim 39, wherein said sample is an unfractionated body fluid or tissue sample.

Claim 41. (new) The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 42. (new) The method of claim 39, wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

Claim 43. (new) The method of claim 39, wherein said patient is a human.

Claim 44. (new) A kit for determining the presence of an isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 comprising: (a) an isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, and (b) an antibody that binds to said isolated biopolymer marker selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 in a sample from a patient.

Claim 45. (new) The kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46. (new) The kit of claim 44, wherein said antibody is labeled.